FDA “Intercenter Institutes” Legislation Headed For Senate Mark-Up
This article was originally published in RPM Report
FDA would be directed to test the concept of joint drug/device/diagnostic reviews in at least one therapeutic area under legislation proposed in the Senate. The idea of further integrating medical product reviews is already part of the Vice President’s cancer “moonshot.”
You may also be interested in...
Former commissioner says agency has to think about getting biggest bang for the buck when considering a reorganization to disease-focused teams.
A Friends of Cancer Research proposal to create FDA drug-device review teams in oncology, cardiology and neurodegenerative disease could find a home in the next round of FDA reform legislation. PDUFA VI. Current and former agency officials are cautiously optimistic about the idea, but combining review operations with different statutory underpinnings will be challenging.
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.